(CercleFinance.com) – Bayer announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended aflibercep in the treatment of age-related macular degeneration (AMD). ) and diabetic macular edema.
If it were to be approved by the European Commission in the coming months, aflibercept 8 mg would allow patients to benefit from a prolonged duration of action, of up to five months.
Aflibercept 8 mg, which the German pharmaceutical group is developing with the American company Regeneron, was approved by the FDA last August.
Yesterday, Bayer announced the signing of a collaboration agreement with another American company, Recursion, in the field of precision oncology.
Under the terms of the research agreement, Recursion could receive up to $1.5 billion in milestone payments and royalties on future drug sales.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
